Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00872170 · ClinicalTrials.gov registry record · Phase 2
Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension
A Phase 2 study of Thalassemia and Hypertension, Pulmonary, sponsored by Carelon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT00872170: Completed Phase 2 study of Thalassemia and Hypertension, Pulmonary, sponsored by Carelon Research.
NCT00872170 is a Phase 2 study of Thalassemia and Hypertension, Pulmonary that has completed, run by Carelon Research. The registered enrollment target is 27 participants, below the 89-participant average among 19 other Thalassemia trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00872170, a Phase 2 study of Thalassemia and Hypertension, Pulmonary, has completed, sponsored by Carelon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
Thalassemia is an inherited blood disorder that can result in mild to severe anemia. Many people with thalassemia also have pulmonary hypertension, which is high blood pressure in the arteries in the lungs. This study will evaluate the safety and effectiveness of the medication sildenafil at reducing blood pressure in the lungs of people with thalassemia and pulmonary hypertension.
Primary Outcome
Change in six-minute walk test (6MWT) distance was calculated as 6MWT at week 12 minus 6MWT at baseline.
Conditions Studied
Interventions
- DRUG Sildenafil
Study Locations (1)
California
- Children's Hospital and Research Institute Oakland - Oakland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
What the finished NCT00872170 record still lists
NCT00872170 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 89-participant average among 19 other Thalassemia trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with Thalassemia appearing as the primary indexed condition, and to 1 intervention - of which Sildenafil is the first listed.
NCT00872170 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00872170 about?
NCT00872170 is a clinical study titled "Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension". Thalassemia is an inherited blood disorder that can result in mild to severe anemia. Many people with thalassemia also have pulmonary hypertension, which is high blood pressure in the arteries in the lungs. This study will evaluate the safety and effectiveness of the medication sildenafil at reducin...
What is the current status of trial NCT00872170?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2009-03. Estimated completion is 2010-11.
What conditions does trial NCT00872170 study?
This clinical trial studies the following conditions: Thalassemia, Hypertension, Pulmonary.
What interventions are being tested in trial NCT00872170?
The interventions under investigation include: Sildenafil (DRUG).
Who is sponsoring clinical trial NCT00872170?
This trial is sponsored by Carelon Research, which has 50 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00872170 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thalassemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00872170's enrollment target sits among peer trials
27 9th of 19 higher than 11 of 19 other Thalassemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thalassemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
COMPLETED · Phase 2
-
Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
COMPLETED · Phase 2
-
Stem Cell Transplant for Hemoglobinopathy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia